191 related articles for article (PubMed ID: 2168343)
1. Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Misko IS; Schmidt C; Martin N; Moss DJ; Sculley TB; Burrows S; Burman KJ
Int J Cancer; 1990 Sep; 46(3):399-404. PubMed ID: 2168343
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells.
Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D
Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385
[TBL] [Abstract][Full Text] [Related]
3. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro.
Rooney CM; Rickinson AB; Moss DJ; Lenoir GM; Epstein MA
Int J Cancer; 1984 Sep; 34(3):339-48. PubMed ID: 6090321
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
5. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claƫsson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
6. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
Rooney CM; Rickinson AB; Moss DJ; Lenoir GM; Epstein MA
IARC Sci Publ; 1985; (60):249-64. PubMed ID: 2998992
[TBL] [Abstract][Full Text] [Related]
7. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
Gregory CD; Murray RJ; Edwards CF; Rickinson AB
J Exp Med; 1988 Jun; 167(6):1811-24. PubMed ID: 2898508
[TBL] [Abstract][Full Text] [Related]
9. AIDS-related Burkitt's-type lymphomas are a target for lymphokine-activated killers induced by interleukin-2 and prolactin.
Gaidano G; Contarini M; Pastore C; Saglio G; Matera L
Proc Soc Exp Biol Med; 1996 Nov; 213(2):196-205. PubMed ID: 8931665
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.
Gregory CD; Edwards CF; Milner A; Wiels J; Lipinski M; Rowe M; Tursz T; Rickinson AB
Int J Cancer; 1988 Aug; 42(2):213-20. PubMed ID: 2841246
[TBL] [Abstract][Full Text] [Related]
11. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
13. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
Zhou MX; Findley HW; Davis R; Ragab AH
Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
[TBL] [Abstract][Full Text] [Related]
14. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
[TBL] [Abstract][Full Text] [Related]
15. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
16. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
18. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.
Wiels J; Lenoir GM; Fellous M; Lipinski M; Salomon JC; Tetaud C; Tursz T
Int J Cancer; 1982 Jun; 29(6):653-8. PubMed ID: 6286514
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers.
Torsteinsdottir S; Masucci MG; Lenoir G; Klein G; Klein E
Cell Immunol; 1984 Jul; 86(2):278-86. PubMed ID: 6329520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]